The FDA has denied Lykos Therapeutics' marketing application for its post-traumatic stress disorder (PTSD) therapy based on MDMA, also known as ecstasy, in a setback for the emerging psychedelic ...

First formed in 1986, MAPS has the express purpose of working with the FDA and DEA to make MDMA-assisted talk therapy an approved, accepted, and available tool to treat PTSD.